Adverse Selection In The Medicare Prescription Drug Program

Centers for Medicare and Medicaid Services Office of Research, Development, and Information in Baltimore, Maryland, USA.
Health Affairs (Impact Factor: 4.97). 11/2009; 28(6):1826-37. DOI: 10.1377/hlthaff.28.6.1826
Source: PubMed

ABSTRACT The Medicare Part D drug benefit created choices for beneficiaries among many prescription drug plans with varying levels of coverage. As a result, Medicare enrollees with high prescription drug costs have strong incentives to enroll in Part D, especially in plans with more comprehensive coverage. To measure this potential problem of "adverse selection," which could threaten plans' finances, we compared baseline characteristics among groups of beneficiaries with various drug coverage arrangements in 2006. We found some significant differences. For example, enrollees in stand-alone prescription drug plans, especially in plans offering benefits in the coverage gap, or "doughnut hole," had higher baseline drug costs and worse health than enrollees in Medicare Advantage prescription drug plans. Although risk-adjusted payments and other measures have been put in place to account for selection, these patterns could adversely affect future Medicare costs and should be watched carefully.

Download full-text


Available from: Melissa A Evans, Dec 15, 2014
11 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: In this paper, the optimal filtering problem for a linear system over observations with a fixed delay is treated, proceeding from the general expression for the stochastic Ito differential of the optimal estimate and its variance. As a result, the optimal filtering equations similar to the traditional Kalman-Bucy filter are obtained in the form dual to the Smith predictor, commonly used control structure for model-based time delay compensation. The paper then presents a robustification algorithm for the obtained optimal filter based on sliding mode compensation of disturbances. As a result, the sliding mode control of observations leading to suppression of the disturbances in a finite time is designed. This control algorithm also guarantees finite-time convergence of the estimate based on the corrupted observations to the optimal estimate satisfying the obtained optimal filtering equations over delayed observations.
    Decision and Control, 2002, Proceedings of the 41st IEEE Conference on; 01/2003
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Clinical guidelines recommend that women with hormone-receptor positive breast cancer receive endocrine therapy (selective estrogen receptor modulators [SERMs] or aromatase inhibitors [AIs]) for five years following diagnosis. To examine utilization and adherence to therapy for SERMs and AIs in Medicare Part D prescription drug plans. Linked Surveillance, Epidemiology, and End Results (SEER)-Medicare data. We identified 15,542 elderly women diagnosed with hormone-receptor positive breast cancer in years 2003-2005 (the latest SEER data at the time of the study) and enrolled in a Part D plan in 2006 or 2007 (the initial years of Part D). This permitted us to compare utilization and adherence to therapy at various points within the recommended five-year timeframe for endocrine therapy. SERM and AI use was measured from claim records. Non-adherence to therapy was defined as a medication possession ratio of less than 80 percent. Between May 2006 and December 2007, 22 percent of beneficiaries received SERM, 52 percent AI, and 26 percent received neither. The percent receiving any endocrine therapy decreased with time from diagnosis. Among SERM and AI users, 20-30 percent were non-adherent to therapy; out-of-pocket costs were higher for AI than SERM and were strongly associated with non-adherence. For AI users without a low income subsidy, adherence to therapy deteriorated after reaching the Part D coverage gap. Many elderly breast cancer patients were not receiving therapy for the recommended five years following diagnosis. Choosing a Part D plan that minimizes out-of-pocket costs is critical to ensuring beneficiary access to essential medications.
    Medicare and Medicaid Research Review 01/2011; 1(4). DOI:10.5600/mmrr.001.04.a04
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Medicare Part D coverage gap has been associated with lower adherence and drug utilization and higher discontinuation. Because osteoporosis has a relatively high prevalence among Medicare-eligible postmenopausal women, we examined changes in utilization of osteoporosis medications during this coverage gap. The purpose of this study was to investigate changes in out-of-pocket (OOP) drug costs and utilization associated with the Medicare Part D coverage gap among postmenopausal beneficiaries with osteoporosis. This retrospective analysis of 2007 pharmacy claims focuses on postmenopausal female Medicare beneficiaries enrolled in full-, partial-, or no-gap exposure standard or Medicare Advantage prescription drug plans (PDPs), retiree drug subsidy (RDS) plans, or the low-income subsidy program. We compared beneficiaries with osteoporosis who were taking teriparatide (Eli Lilly and Company, Indianapolis, Indiana) (n = 5657) with matched samples of beneficiaries who were taking nonteriparatide osteoporosis medications (NTO; n = 16,971) or who had other chronic conditions (OCC; n = 16,971). We measured average monthly prescription drug fills and OOP costs, medication discontinuation, and skipping. More than half the sample reached the coverage gap; OOP costs then rose for teriparatide users enrolled in partial- or full-gap exposure plans (increase of 121% and 186%; $300 and $349) but fell for those in no-gap exposure PDPs or RDS plans (decrease of 49% and 30%; $131 and $40). OOP costs for beneficiaries in partial- or full-gap exposure PDPs increased >120% (increase of $144 and $176) in the NTO group and nearly doubled for the OCC group (increase of $124 and $151); these OOP costs were substantially lower than those for teriparatide users. Both teriparatide users and NTO group members discontinued or skipped medications more often than persons in the OCC group, regardless of plan or benefit design. Medication discontinuation and OOP costs among beneficiaries with osteoporosis were highest for those enrolled in Part D plans with a coverage gap. Providers should be aware of potential cost-related nonadherence among Medicare beneficiaries taking osteoporosis medications.
    05/2011; 9(4):241-9. DOI:10.1016/j.amjopharm.2011.04.009
Show more